SCYXSCYNEXIS, Inc.
$4.19-34% 1Y
$4.19
$3.5752 weeks$8.88
Price
-34%1YEnd-of-day closes, not the intraday tick.
The five questions
2 of 5 availableOnly two of the five can be answered for SCYX today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Watch
P/En/a
Market value$332.9M
1 year-34%
5 years-90%
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 28, 2026On September 25, 2026, SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) entered into an Award/Contract (the “BARDA Contract”) with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human …Material agreement entered · Form 8-K
- Sep 22, 2026On September 18, 2026, the Board of Directors (the “Board”) of SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) appointed Steven K. Burke, M.D., as a member of the Board, effective September 18, 2026.Director or officer change · Form 8-K
- Sep 10, 2026Departure of Chief Financial Officer On September 9, 2026, the then-current Chief Financial Officer of SCYNEXIS, Inc. (the “Company” or “SCYNEXIS”), Ivor Macleod, CPA, MBA, notified the Company of his intent to retire.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Drug Manufacturers, Specialty & Generic
The closest names by size in the same industry